Ex-Div Reminder for First Mid-Illinois Bancshares (FMBH)

Looking at the universe of stocks we cover at Dividend Channel, on 11/25/14, First Mid-Illinois Bancshares, Inc. (FMBH) will trade ex-dividend, for its semi-annual dividend of $0.29, payable on 12/8/14. As a percentage of FMBH's recent stock price of $21.00, this dividend works out to approximately 1.38%, so look for shares of First Mid-Illinois Bancshares, Inc. to trade 1.38% lower — all else being equal — when FMBH shares open for trading on 11/25/14.

START SLIDESHOW:
Click here to learn which 25 S.A.F.E. dividend stocks should be on your radar screen »

Below is a dividend history chart for FMBH, showing historical dividends prior to the most recent $0.29 declared by First Mid-Illinois Bancshares, Inc.:

FMBH+Dividend+History+Chart

In general, dividends are not always predictable; but looking at the history above can help in judging whether the most recent dividend from FMBH is likely to continue, and whether the current estimated yield of 2.76% on annualized basis is a reasonable expectation of annual yield going forward.The chart below shows the one year performance of FMBH shares, versus its 200 day moving average:

First Mid-Illinois Bancshares, Inc. 200 Day Moving Average Chart

Looking at the chart above, FMBH's low point in its 52 week range is $18.56 per share, with $23.80 as the 52 week high point — that compares with a last trade of $21.00.

In Friday trading, First Mid-Illinois Bancshares, Inc. shares are currently trading flat on the day.

More from Stocks

CalAmp Shares Plunge on Revised Guidance, Analyst Downgrades

CalAmp Shares Plunge on Revised Guidance, Analyst Downgrades

Dow Rises but Off Highs Amid Progress in U.S.-China Trade Talks

Dow Rises but Off Highs Amid Progress in U.S.-China Trade Talks

Ford, GM Leap on Report China Preparing to Slash US Import Tariffs

Ford, GM Leap on Report China Preparing to Slash US Import Tariffs

McDonald's Limited Risk Is Appealing to Conservative Investors

McDonald's Limited Risk Is Appealing to Conservative Investors

Pfizer Slips After JPMorgan Downgrade on Patent Cycle Concerns

Pfizer Slips After JPMorgan Downgrade on Patent Cycle Concerns